Literature DB >> 22503427

The development of a QALY measure for epilepsy: NEWQOL-6D.

Brendan Mulhern1, Donna Rowen, Ann Jacoby, Tony Marson, Dee Snape, Dyfrig Hughes, Nick Latimer, Gus A Baker, John E Brazier.   

Abstract

Cost-utility analysis is used to inform the allocation of healthcare resources, using the quality-adjusted life year (QALY) as the outcome measure. We report the development of an epilepsy-specific QALY measure (NEWQOL-6D) derived from the NEWQOL measure of health-related quality of life. Firstly, psychometric and Rasch analyses established the dimension structure of NEWQOL and generated a reduced health state classification system including one item per dimension. Secondly, health states generated by the classification system were valued using Time Trade Off, and the results were modeled to generate a utility score for every health state. A classification system with 6 dimensions (worry about attacks; depression; memory; concentration; stigma; control) was produced, and generalized least squares regression was used to generate utility scores for every health state. This study is the first attempt to derive an epilepsy-specific QALY measure, and the utility values can be used in the economic evaluation of emerging technologies for epilepsy.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22503427     DOI: 10.1016/j.yebeh.2012.02.025

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  13 in total

Review 1.  Conducting Economic Evaluations Alongside Randomised Trials: Current Methodological Issues and Novel Approaches.

Authors:  Dyfrig Hughes; Joanna Charles; Dalia Dawoud; Rhiannon Tudor Edwards; Emily Holmes; Carys Jones; Paul Parham; Catrin Plumpton; Colin Ridyard; Huw Lloyd-Williams; Eifiona Wood; Seow Tien Yeo
Journal:  Pharmacoeconomics       Date:  2016-05       Impact factor: 4.981

Review 2.  An educational review of the statistical issues in analysing utility data for cost-utility analysis.

Authors:  Rachael Maree Hunter; Gianluca Baio; Thomas Butt; Stephen Morris; Jeff Round; Nick Freemantle
Journal:  Pharmacoeconomics       Date:  2015-04       Impact factor: 4.981

Review 3.  The Role of Condition-Specific Preference-Based Measures in Health Technology Assessment.

Authors:  Donna Rowen; John Brazier; Roberta Ara; Ismail Azzabi Zouraq
Journal:  Pharmacoeconomics       Date:  2017-12       Impact factor: 4.981

Review 4.  Dimensions Used in Instruments for QALY Calculation: A Systematic Review.

Authors:  Moustapha Touré; Christian R C Kouakou; Thomas G Poder
Journal:  Int J Environ Res Public Health       Date:  2021-04-21       Impact factor: 3.390

5.  Defining health-related quality of life for young wheelchair users: A qualitative health economics study.

Authors:  Nathan Bray; Jane Noyes; Nigel Harris; Rhiannon Tudor Edwards
Journal:  PLoS One       Date:  2017-06-15       Impact factor: 3.240

6.  Sensitivity and responsiveness of the EQ-5D-3L in patients with uncontrolled focal seizures: an analysis of Phase III trials of adjunctive brivaracetam.

Authors:  Clara Mukuria; Tracey Young; Anju Keetharuth; Simon Borghs; John Brazier
Journal:  Qual Life Res       Date:  2016-12-21       Impact factor: 4.147

7.  Australian Utility Weights for the EORTC QLU-C10D, a Multi-Attribute Utility Instrument Derived from the Cancer-Specific Quality of Life Questionnaire, EORTC QLQ-C30.

Authors:  Madeleine T King; Rosalie Viney; A Simon Pickard; Donna Rowen; Neil K Aaronson; John E Brazier; David Cella; Daniel S J Costa; Peter M Fayers; Georg Kemmler; Helen McTaggart-Cowen; Rebecca Mercieca-Bebber; Stuart Peacock; Deborah J Street; Tracey A Young; Richard Norman
Journal:  Pharmacoeconomics       Date:  2018-02       Impact factor: 4.981

8.  Assessment of the psychometric properties and refinement of the Health and Self-Management in Diabetes Questionnaire (HASMID).

Authors:  Jill Carlton; Donna Rowen; Jackie Elliott
Journal:  Health Qual Life Outcomes       Date:  2020-03-05       Impact factor: 3.186

9.  Is the EQ-5D fit for purpose in asthma? Acceptability and content validity from the patient perspective.

Authors:  Diane Whalley; Gary Globe; Rebecca Crawford; Lynda Doward; Eskinder Tafesse; John Brazier; David Price
Journal:  Health Qual Life Outcomes       Date:  2018-08-03       Impact factor: 3.186

10.  Patient-Focused Drug Development Methods for Benefit-Risk Assessments: A Case Study Using a Discrete Choice Experiment for Antiepileptic Drugs.

Authors:  Emily A F Holmes; Catrin Plumpton; Gus A Baker; Ann Jacoby; Adele Ring; Paula Williamson; Anthony Marson; Dyfrig A Hughes
Journal:  Clin Pharmacol Ther       Date:  2018-10-25       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.